PTPN2-blocked immune cell and application and preparation thereof

Although CAR-T cell therapy shines in the treatment of hematological tumors, it does not have a good therapeutic effect on solid tumors. T cells are not easy to enter the...

Term CAR: The design of chimeric antigen receptor CARs has gone through the following process: the first generation CAR has only one intracellular signaling component CD3ζ or FcγRI molecule, and because there is only one activation domain in the cell, it can only cause transient T cell proliferation and less cytokine secretion, but can not provide long-term T cell proliferation signal and sustained anti-tumor effect in vivo, so it has not achieved good clinical efficacy. The second-generation CARs introduce a co-stimulatory molecule based on the original structure, such as CD28, 4-1BB, OX40, and ICOS. Compared with the first-generation CARs, the function is greatly improved, and the persistence of CAR-T cells and the ability to treat tumor cells are further enhanced. lethality. On the basis of the second-generation CARs, some new immune co-stimulatory molecules such as CD27 and CD134 are connected in series to develop into the third-generation and fourth-generation CARs, and there are also double-ta...